Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

Forskningsoutput: TidskriftsbidragÖversiktsartikel


The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics.


  • Giovanni B. Frisoni
  • Marina Boccardi
  • Frederik Barkhof
  • Kaj Blennow
  • Stefano F Cappa
  • Konstantinos Chiotis
  • Jean Francois Démonet
  • Valentina Garibotto
  • Panteleimon Giannakopoulos
  • Anton Gietl
  • Karl Herholz
  • Clifford R Jack
  • Flavio Nobili
  • Agneta Nordberg
  • Heather M. Snyder
  • Mara Ten Kate
  • Andrea Varrone
  • Emiliano Albanese
  • Stefanie Becker
  • Patrick Bossuyt
  • Maria C. Carrillo
  • Chiara Cerami
  • Bruno Dubois
  • Valentina Gallo
  • Ezio Giacobini
  • Gabriel Gold
  • Samia A. Hurst
  • Anders Lönneborg
  • Karl Olof Lovblad
  • José Luis Molinuevo
  • Andreas U. Monsch
  • Urs Mosimann
  • Alessandro Padovani
  • Agnese Picco
  • Corinna Porteri
  • Osman Ratib
  • Laure Saint-Aubert
  • Charles Scerri
  • Philip Scheltens
  • Jonathan M Schott
  • Ida Sonni
  • Stefan Teipel
  • Paolo Vineis
  • Pieter Jelle Visser
  • Yutaka Yasui
  • Bengt Winblad
Enheter & grupper
Externa organisationer
  • University of Geneva
  • Centro San Giovanni di Dio Fatebenefratelli
  • VU University Medical Center
  • University College London
  • European Society of Neuroradiology
  • Sahlgrenska Academy
  • Sahlgrenska University Hospital
  • Institute for Advanced Studies (IUSS), Pavia
  • Karolinska Institute
  • Lausanne University Hospital
  • University of Zurich
  • Skåne University Hospital
  • University of Manchester
  • Mayo Clinic Minnesota
  • University of Genoa
  • Azienda Ospedaliera Universitaria San Martino IST
  • Karolinska University Hospital
  • Alzheimer's Association: Alzheimer's Disease and Dementia
  • Stockholm County Council
  • Alzheimer's Switzerland
  • Academic Medical Center
  • University Vita-Salute San Raffaele
  • San Raffaele Scientific Institute
  • Pierre and Marie Curie University
  • Queen Mary University
  • Geneva University Hospital
  • Pasqual Maragall Foundation for Research on Alzheimer
  • Felix Platter Hospital
  • University of Bern
  • University of Brescia
  • University of Malta
  • Alzheimer Europe
  • Stanford University
  • German Center for Neurodegenerative Diseases
  • University of Rostock
  • Imperial College London
  • Maastricht University
  • St Jude Children´s Research Hospital, Memphis
  • European Alzheimer's Disease Consortium (EADC)

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurologi
Sidor (från-till)661-676
Antal sidor16
TidskriftThe Lancet Neurology
Utgåva nummer8
StatusPublished - 2017 aug 1
Peer review utfördJa